- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI | 306 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first... ► Artikel lesen | |
| 10.07. | Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease | 1 | Benzinga.com | ||
| 10.07. | Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI | 212 | GlobeNewswire (Europe) | JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially... ► Artikel lesen | |
| 02.07. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.07. | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 368 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
| 02.07. | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 6 | Investing.com Deutsch | ||
| 02.07. | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
| 02.07. | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 147 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
| 27.06. | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha | ||
| 27.06. | Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement | 133 | GlobeNewswire (Europe) | FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment... ► Artikel lesen | |
| 14.05. | EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models | 2 | Benzinga.com | ||
| 13.05. | Channel Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Channel Therapeutics Corporation: Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules | 1 | GlobeNewswire (USA) | ||
| 01.05. | Channel Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 17.04. | Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi | 1 | FiercePharma | ||
| 17.04. | Ligand unit Pelthos to merge with Channel Therapeutics | 1 | Seeking Alpha | ||
| 17.04. | Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub | 429 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries... ► Artikel lesen | |
| 17.04. | Channel Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | 307 | GlobeNewswire (Europe) | Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug... ► Artikel lesen | |
| 27.03. | Channel Therapeutics Corp - 10-K, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,218 | -16,60 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VALNEVA | 2,648 | -0,38 % | Valneva Aktie zündet nach Impfstoff-News - oder doch nur ein Strohfeuer? | Die Valneva Aktie reagierte am Montag mit einem Kurssprung auf die Meldung, dass die Europäische Arzneimittel-Agentur EMA nach positiver Prüfung die Altersbeschränkung für den Chikungunya-Impfstoff... ► Artikel lesen | |
| MAINZ BIOMED | 2,110 | +11,05 % | EQS-News: Mainz BioMed N.V.: Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest der nächsten Generation und Portfolio-Erweiterung durch Erwerb im Bereich Pankreaskrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,040 | +0,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,340 | +0,53 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics: Oppenheimer erhöht Kursziel auf 14 US-Dollar | ||
| REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| 180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets | PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector... ► Artikel lesen | |
| ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,130 | +2,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,210 | +0,03 % | Truist Securities initiates Harmony Biosciences stock with Buy rating | ||
| KYMERA THERAPEUTICS | 45,140 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? |
PELTHOS THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 19,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.